How the Teva-Actavis Deal Benefits Teva



About Teva Pharmaceutical

Teva Pharmaceutical (TEVA) is a world leader in the generic pharmaceutical industry. The company also deals with innovative pharmaceuticals, for which the focus areas include treatment products for central nervous system and respiratory conditions.

Nearly 45% of Teva’s total revenue comes from the US markets, while 32% of its revenue comes from the European markets.

The above chart shows Teva’s position in the global pharmaceutical industry. Teva is the ninth-largest pharmaceutical company worldwide.

Article continues below advertisement


Actavis (ACT) was a global pharmaceutical company focused on developing, manufacturing, and commercializing innovative branded pharmaceutical, high-quality generic, and over-the-counter medicines. As discussed earlier, Actavis completed its Allergan (AGN) acquisition on March 17, 2015. Actavis was merged into Allergan, and Allergan continues as the surviving company.

Following the merger, Allergan is an indirect, wholly-owned subsidiary of Actavis. Further details of the deal are discussed in How Actavis and Allergan Merger May Boost Branded Business.

Teva-Actavis synergies

An abbreviated new drug application is filed by a generic pharmaceutical company in the United States for approval of a generic version of a patented drug. Teva has around 130 abbreviated new drug applications, while Actavis (now Allergan) has around 200 abbreviated new drug applications. So, the combined entity will have approximately 320 abbreviated new drug applications.

Teva competes with Novartis (NVS), Boehringer Ingelheim, GlaxoSmithKline (GSK), Merck & Co. (MRK), Biogen (BIIB), and Genzyme (GENZ) on various products.

In order to divest risk, investors can consider ETFs such as the PowerShares International Dividend Achievers ETF (PID) or the VanEck Vectors Pharmaceutical ETF (PPH), which have holdings in Teva.


More From Market Realist